These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21237497)

  • 1. Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review.
    Pelz AF; Agaimy A; Daniels M; Evert M; Schulz HU; Lüders P; Müller G; Lasota J; Röpke A; Wieacker P; Miettinen M; Schneider-Stock R
    Hum Pathol; 2011 Apr; 42(4):586-93. PubMed ID: 21237497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
    Lam MM; Corless CL; Goldblum JR; Heinrich MC; Downs-Kelly E; Rubin BP
    Int J Gynecol Pathol; 2006 Jul; 25(3):288-92. PubMed ID: 16810068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal stromal tumor arising in the rectovaginal septum.
    Vázquez J; Pérez-Peña M; González B; Sánchez A
    J Low Genit Tract Dis; 2012 Apr; 16(2):158-61. PubMed ID: 22371045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation.
    Cho J; Kang GH; Kim KM; Park J; Shim YM
    Pathology; 2012 Apr; 44(3):260-1. PubMed ID: 22437744
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
    Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions.
    Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
    Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
    Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
    Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumors of the vermiform appendix: clinicopathologic, immunohistochemical, and molecular study of 2 cases with literature review.
    Agaimy A; Pelz AF; Wieacker P; Roessner A; Wünsch PH; Schneider-Stock R
    Hum Pathol; 2008 Aug; 39(8):1252-7. PubMed ID: 18547614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Curative resection for bulky rectal gastrointestinal stromal tumor after neoadjuvant imatinib mesylate].
    Kobayashi H; Uetake H; Higuchi T; Enomoto M; Yasuno M; Iida S; Yoshimura T; Ishikawa T; Ishiguro M; Kato S; Ono H; Kikuchi A; Yamauchi S; Sugihara K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2620-2. PubMed ID: 21224658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sporadic multiple gastrointestinal stromal tumor with unique clinical and molecular features.
    Pera M; Iglesias M; Puig S; Martínez-Avilés L; Bellosillo B
    Hum Pathol; 2011 Aug; 42(8):1194-9. PubMed ID: 21295327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
    Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases.
    Herawi M; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2006 Nov; 30(11):1389-95. PubMed ID: 17063078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.